Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Quinazolines. Found 11 abstracts

Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug;40(4):393-8.   PMCID: PMC5026539
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15;21(16):3610-8.   PMCID: 4790106
Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clin Breast Cancer. 2014 Feb;14(1):e14-6.
Ali SM, Alpaugh RK, Downing SR, Stephens PJ, Yu JQ, Wu H, Buell JK, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol. 2014 Sep;32(25):e88-91.   PMCID: 4876358
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical Cancer Research. 2010 Mar 15;16(6):1904-14.   PMCID: NIHMS352308
Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009 Jul;19(5):929-33.   PMCID: PMC2722934
Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. J Clin Oncol. 2007 Jun;25(16):2152-5.
Langer CJ. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar;25(7):751-3.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):991-1002.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Quinazolines

Quinazolines therapeutic use Epidermal Growth Factor Receptor drug therapy Middle Aged Female pathology Aged antagonists & inhibitors administration & dosage Treatment Outcome Adult genetics metabolism Monoclonal Antibodies Protein Kinase Inhibitors adverse effects 80 and over Aged Squamous Cell Carcinoma Antineoplastic Agents ErbB-2 Receptor Cisplatin Disease-Free Survival Human Male Molecular Targeted Therapy Head and Neck Neoplasms Survival Rate therapy Non-Small-Cell Lung Carcinoma mortality Inflammatory Breast Neoplasms Piperidines Lung Neoplasms Antineoplastic Combined Chemotherapy Protocols Neoplasm Metastasis Combined Modality Therapy methods Adenocarcinoma Radiotherapy Epidermal Growth Factor) EC 2-7-1-112 (Receptor Double-Blind Method Triple Negative Breast Neoplasms Her2 psychology Esophagogastric Junction Colorectal Neoplasms Prognosis Fluorouracil Triazoles Kaplan-Meier Estimate pd [Pharmacology] 0 (cetuximab) Esophageal Neoplasms Monoclonal) 0 (Antibodies Glioblastoma Ductal Carcinoma-Breast Inflammatory breast cancer radiotherapy Polymerase Chain Reaction Estrogen Receptors Next-generation sequencing Trastuzumab Inhibitors] Antineoplastic Combined Chemotherapy Carboplatin Mutation blood Uterine Cervical Neoplasms enzymology Quality of Life Nitriles Maximum Tolerated Dose Neoplasm Proteins inhibitors 0 (erlotinib) Age Factors Chemoradiotherapy 0 (Quinazolines) pharmacokinetics surgery EC 2-7-1-112 (Protein-Tyrosine Kinase) Histone Deacetylases secondary Lymphatic Metastasis Postmenopause erbB-2 Receptor Hormone-Dependent Neoplasms Breast Neoplasms Hydroxamic Acids 0 (Antineoplastic Agents) Clinical Trials antagonists & Tissue Distribution tu [Therapeutic Use] Immunohistochemistry Lapatinib Dacarbazine ai [Antagonists & Inhibitors] Gene Dosage Karnofsky Performance Status Protein-Tyrosine Kinase ai [Antagonists & Protocols Esophagectomy Progesterone Receptors Paclitaxel Prospective Studies analogs & derivatives 184475-35-2 (gefitinib) drug effects dt [Drug Therapy] analysis
Last updated on Friday, January 03, 2020